{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T09:22:51Z","timestamp":1787563371116,"version":"build-2736575974"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"JSPS KAKENHI","award":["23K19481"],"award-info":[{"award-number":["23K19481"]}]},{"name":"JSPS KAKENHI","award":["23K09670"],"award-info":[{"award-number":["23K09670"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Virol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s00705-026-06665-7","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T15:13:08Z","timestamp":1780585988000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["In vitro efficacy of anti-influenza active compounds against clinical isolates with high growth capability"],"prefix":"10.1007","volume":"171","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-6041-2409","authenticated-orcid":false,"given":"Waldy Yudha","family":"Perdana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akeno","family":"Tsuneki-Tokunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4871-4259","authenticated-orcid":false,"given":"Koyuki Atifa","family":"Rahmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4761-1514","authenticated-orcid":false,"suffix":"Jr.","given":"Alfredo A.","family":"Hinay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7984-207X","authenticated-orcid":false,"given":"Kyosuke","family":"Kanai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5220-6137","authenticated-orcid":false,"given":"Seiji","family":"Kageyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"6665_CR1","unstructured":"World Health Organization (2025) Influenza (seasonal). https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/influenza-(seasonal)"},{"key":"6665_CR2","volume-title":"Guidelines for the clinical management of severe illness from influenza virus infections","author":"World Health Organization","year":"2022","unstructured":"World Health Organization (2022) Guidelines for the clinical management of severe illness from influenza virus infections. World Health Organization, Geneva"},{"key":"6665_CR3","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.3390\/ijerph19053018","volume":"19","author":"M \u015awierczy\u0144ska","year":"2022","unstructured":"\u015awierczy\u0144ska M, Mirowska-Guzel DM, Pindelska E (2022) Antiviral drugs in influenza. Int J Environ Res Public Health 19:3018. https:\/\/doi.org\/10.3390\/ijerph19053018","journal-title":"Int J Environ Res Public Health"},{"key":"6665_CR4","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1093\/infdis\/jiv288","volume":"212","author":"AG L\u2019Huillier","year":"2015","unstructured":"L\u2019Huillier AG, Abed Y, Petty TJ et al (2015) E119D neuraminidase mutation conferring pan-resistance to neuraminidase inhibitors in an A(H1N1)pdm09 isolate from a stem-cell transplant recipient. J Infect Dis 212:1726\u20131734. https:\/\/doi.org\/10.1093\/infdis\/jiv288","journal-title":"J Infect Dis"},{"key":"6665_CR5","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1093\/infdis\/jiv245","volume":"212","author":"D Tamura","year":"2015","unstructured":"Tamura D, DeBiasi RL, Okomo-Adhiambo M et al (2015) Emergence of multidrug-resistant influenza A(H1N1)pdm09 virus variants in an immunocompromised child treated with oseltamivir and zanamivir. J Infect Dis 212:1209\u20131213. https:\/\/doi.org\/10.1093\/infdis\/jiv245","journal-title":"J Infect Dis"},{"key":"6665_CR6","doi-asserted-by":"publisher","first-page":"105281","DOI":"10.1016\/j.antiviral.2022.105281","volume":"200","author":"EA Govorkova","year":"2022","unstructured":"Govorkova EA, Takashita E, Daniels RS et al (2022) Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2018\u20132020. Antiviral Res 200:105281. https:\/\/doi.org\/10.1016\/j.antiviral.2022.105281","journal-title":"Antiviral Res"},{"key":"6665_CR7","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1177\/135965350701200401","volume":"12","author":"R Medeiros","year":"2007","unstructured":"Medeiros R, Rameix-Welti M-A, Lorin V et al (2007) Failure of zanamivir therapy for pneumonia in a bone-marrow transplant recipient infected by a zanamivir-sensitive influenza a (H1N1) virus. Antivir Ther 12:571\u2013576. https:\/\/doi.org\/10.1177\/135965350701200401","journal-title":"Antivir Ther"},{"key":"6665_CR8","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1164\/ajrccm.182.10.1334","volume":"182","author":"S Busani","year":"2010","unstructured":"Busani S, Girardis M, Biagioni E et al (2010) Surfactant therapy and intravenous zanamivir in severe respiratory failure due to persistent influenza A\/H1N1 2009 virus infection. Am J Respir Crit Care Med 182:1334\u20131334. https:\/\/doi.org\/10.1164\/ajrccm.182.10.1334","journal-title":"Am J Respir Crit Care Med"},{"key":"6665_CR9","doi-asserted-by":"publisher","first-page":"495","DOI":"10.3109\/00365548.2011.556144","volume":"43","author":"E Petersen","year":"2011","unstructured":"Petersen E, Keld DB, Ellermann-Eriksen S et al (2011) Failure of combination oral oseltamivir and inhaled zanamivir antiviral treatment in ventilator- and ECMO-treated critically ill patients with pandemic influenza A (H1N1)v. Scand J Infect Dis 43:495\u2013503. https:\/\/doi.org\/10.3109\/00365548.2011.556144","journal-title":"Scand J Infect Dis"},{"key":"6665_CR10","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1086\/600383","volume":"200","author":"N Lee","year":"2009","unstructured":"Lee N, Chan PKS, Hui DSC et al (2009) Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis 200:492\u2013500. https:\/\/doi.org\/10.1086\/600383","journal-title":"J Infect Dis"},{"key":"6665_CR11","doi-asserted-by":"publisher","first-page":"104761","DOI":"10.1016\/j.jcv.2021.104761","volume":"136","author":"C Pronier","year":"2021","unstructured":"Pronier C, Gacouin A, Lagathu G et al (2021) Respiratory Influenza viral load as a marker of poor prognosis in patients with severe symptoms. J Clin Virol 136:104761. https:\/\/doi.org\/10.1016\/j.jcv.2021.104761","journal-title":"J Clin Virol"},{"key":"6665_CR12","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s10096-019-03514-1","volume":"38","author":"A Lalueza","year":"2019","unstructured":"Lalueza A, Folgueira D, Mu\u00f1oz-Gallego I et al (2019) Influence of viral load in the outcome of hospitalized patients with influenza virus infection. Eur J Clin Microbiol Infect Dis 38:667\u2013673. https:\/\/doi.org\/10.1007\/s10096-019-03514-1","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"6665_CR13","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1111\/j.1556-4029.2012.02180.x","volume":"57","author":"C Boulagnon","year":"2012","unstructured":"Boulagnon C, Leveque N, Renois F et al (2012) Influenza A\/H1N1 (2009) infection as a cause of unexpected out-of-hospital death in the young. J Forensic Sci 57:1650\u20131655. https:\/\/doi.org\/10.1111\/j.1556-4029.2012.02180.x","journal-title":"J Forensic Sci"},{"key":"6665_CR14","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1007\/S00705-021-04976-5","volume":"166","author":"A Tsuneki-Tokunaga","year":"2021","unstructured":"Tsuneki-Tokunaga A, Kanai K, Itagaki A et al (2021) Growth capability of epidemic influenza viruses in Japan since the 2009 H1N1 pandemic. Arch Virol 166:1193\u20131196. https:\/\/doi.org\/10.1007\/S00705-021-04976-5","journal-title":"Arch Virol"},{"key":"6665_CR15","doi-asserted-by":"publisher","first-page":"110717","DOI":"10.1016\/j.virol.2025.110717","volume":"613","author":"A Tsuneki-Tokunaga","year":"2026","unstructured":"Tsuneki-Tokunaga A, Komatsu M, Perdana WY et al (2026) Epidemic influenza virus strains with high growth capability induce severe inflammatory response in vivo. Virology 613:110717. https:\/\/doi.org\/10.1016\/j.virol.2025.110717","journal-title":"Virology"},{"key":"6665_CR16","unstructured":"World Health Organization (WHO) (2024) Summary of neuraminidase (NA) amino acid substitutions assessed for their effects on inhibition by neuraminidase inhibitors (NAIs). https:\/\/cdn.who.int\/media\/docs\/default-source\/influenza\/laboratory---network\/quality-assurance\/human-nai-marker-table_for-publication_final_20240918.pdf?sfvrsn=c6d153ec_3. Accessed 27 Feb 2025"},{"key":"6665_CR17","unstructured":"World Health Organization (WHO) (2024) Summary of polymerase acidic protein (PA) amino acid substitutions assessed for their effects on PA inhibitor (PAI) baloxavir susceptibility. https:\/\/cdn.who.int\/media\/docs\/default-source\/influenza\/laboratory---network\/quality-assurance\/antiviral-susceptibility-influenza\/pa-marker-who-table_07-08-2024_updated_final-version.pdf?sfvrsn=5307d6fe_2&download=true. Accessed 27 Feb 2025"},{"key":"6665_CR18","doi-asserted-by":"publisher","first-page":"10309","DOI":"10.1128\/JVI.01109-09","volume":"83","author":"B Zhou","year":"2009","unstructured":"Zhou B, Donnelly ME, Scholes DT et al (2009) Single-reaction genomic amplification accelerates sequencing and vaccine production for classical and swine origin human influenza a viruses. J Virol 83:10309\u201310313. https:\/\/doi.org\/10.1128\/JVI.01109-09","journal-title":"J Virol"},{"key":"6665_CR19","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jcv.2010.08.006","volume":"49","author":"JB Mahony","year":"2010","unstructured":"Mahony JB, Chong S, Luinstra K et al (2010) Development of a novel bead-based multiplex PCR assay for combined subtyping and oseltamivir resistance genotyping (H275Y) of seasonal and pandemic H1N1 influenza A viruses. J Clin Virol 49:277\u2013282. https:\/\/doi.org\/10.1016\/j.jcv.2010.08.006","journal-title":"J Clin Virol"},{"key":"6665_CR20","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1056\/NEJMoa0903810","volume":"360","author":"FS Dawood","year":"2009","unstructured":"Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S, Garten RJ, Gubareva LV, Xu X, Bridges CB, Uyeki TM (2009) Emergence of a novel swine-origin influenza A (H1N1) virus in humans. New Engl J Med 360:2605\u20132615. https:\/\/doi.org\/10.1056\/NEJMoa0903810","journal-title":"New Engl J Med"},{"key":"6665_CR21","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1007\/s10096-011-1482-9","volume":"31","author":"M Redlberger-Fritz","year":"2012","unstructured":"Redlberger-Fritz M, Aberle SW, Strassl R, Popow-Kraupp T (2012) Rapid identification of neuraminidase inhibitor resistance mutations in seasonal influenza virus A(H1N1), A(H1N1)2009, and A(H3N2) subtypes by melting point analysis. Eur J Clin Microbiol Infect Dis 31:1593\u20131601. https:\/\/doi.org\/10.1007\/s10096-011-1482-9","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"6665_CR22","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jcv.2015.04.019","volume":"68","author":"Y-M Deng","year":"2015","unstructured":"Deng Y-M, Spirason N, Iannello P et al (2015) A simplified Sanger sequencing method for full genome sequencing of multiple subtypes of human influenza A viruses. J Clin Virol 68:43\u201348. https:\/\/doi.org\/10.1016\/j.jcv.2015.04.019","journal-title":"J Clin Virol"},{"key":"6665_CR23","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1128\/JCM.01435-09","volume":"48","author":"G Chidlow","year":"2010","unstructured":"Chidlow G, Harnett G, Williams S et al (2010) Duplex real-time reverse transcriptase PCR assays for rapid detection and identification of pandemic (H1N1) 2009 and seasonal influenza A\/H1, A\/H3, and B viruses. J Clin Microbiol 48:862\u2013866. https:\/\/doi.org\/10.1128\/JCM.01435-09","journal-title":"J Clin Microbiol"},{"key":"6665_CR24","doi-asserted-by":"publisher","first-page":"ii5","DOI":"10.1093\/jac\/dkq015","volume":"65","author":"BE Davies","year":"2010","unstructured":"Davies BE (2010) Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations. J Antimicrob Chemother 65:ii5\u2013ii10. https:\/\/doi.org\/10.1093\/jac\/dkq015","journal-title":"J Antimicrob Chemother"},{"key":"6665_CR25","doi-asserted-by":"publisher","first-page":"e0220908","DOI":"10.1371\/journal.pone.0220908","volume":"14","author":"DR Hijano","year":"2019","unstructured":"Hijano DR, Brazelton de Cardenas J, Maron G et al (2019) Clinical correlation of influenza and respiratory syncytial virus load measured by digital PCR. PLoS One 14:e0220908. https:\/\/doi.org\/10.1371\/journal.pone.0220908","journal-title":"PLoS One"},{"key":"6665_CR26","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1128\/AAC.45.3.743-748.2001","volume":"45","author":"DF Smee","year":"2001","unstructured":"Smee DF, Huffman JH, Morrison AC et al (2001) Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities. Antimicrob Agents Chemother 45:743\u2013748. https:\/\/doi.org\/10.1128\/AAC.45.3.743-748.2001","journal-title":"Antimicrob Agents Chemother"},{"key":"6665_CR27","doi-asserted-by":"publisher","first-page":"5178","DOI":"10.1128\/AAC.00703-11","volume":"55","author":"MJ Shelton","year":"2011","unstructured":"Shelton MJ, Lovern M, Ng-Cashin J et al (2011) Zanamivir pharmacokinetics and pulmonary penetration into epithelial lining fluid following intravenous or oral inhaled administration to healthy adult subjects. Antimicrob Agents Chemother 55:5178\u20135184. https:\/\/doi.org\/10.1128\/AAC.00703-11","journal-title":"Antimicrob Agents Chemother"},{"key":"6665_CR28","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nmeth.2089","volume":"9","author":"CA Schneider","year":"2012","unstructured":"Schneider CA, Rasband WS, Eliceiri KW (2012) NIH Image to ImageJ: 25 years of image analysis. Nat Methods 9:671\u2013675. https:\/\/doi.org\/10.1038\/nmeth.2089","journal-title":"Nat Methods"},{"key":"6665_CR29","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/s10096-020-03840-9","volume":"39","author":"T Lampejo","year":"2020","unstructured":"Lampejo T (2020) Influenza and antiviral resistance: an overview. Eur J Clin Microbiol Infect Dis 39:1201\u20131208. https:\/\/doi.org\/10.1007\/s10096-020-03840-9","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"6665_CR30","doi-asserted-by":"publisher","first-page":"2429627","DOI":"10.1080\/22221751.2024.2429627","volume":"13","author":"J Xu","year":"2024","unstructured":"Xu J, Luo Q, Huang Y et al (2024) Influenza neuraminidase mutations and resistance to neuraminidase inhibitors. Emerg Microbes Infect 13:2429627. https:\/\/doi.org\/10.1080\/22221751.2024.2429627","journal-title":"Emerg Microbes Infect"},{"key":"6665_CR31","doi-asserted-by":"publisher","first-page":"9633","DOI":"10.1038\/s41598-018-27890-4","volume":"8","author":"S Omoto","year":"2018","unstructured":"Omoto S, Speranzini V, Hashimoto T et al (2018) Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil. Sci Rep 8:9633. https:\/\/doi.org\/10.1038\/s41598-018-27890-4","journal-title":"Sci Rep"},{"key":"6665_CR32","doi-asserted-by":"publisher","first-page":"S2248","DOI":"10.21037\/jtd.2018.03.169","volume":"10","author":"Z Li","year":"2018","unstructured":"Li Z, Li L, Zhao S et al (2018) Re-understanding anti-influenza strategy: attach equal importance to antiviral and anti-inflammatory therapies. J Thorac Dis 10:S2248\u2013S2259. https:\/\/doi.org\/10.21037\/jtd.2018.03.169","journal-title":"J Thorac Dis"},{"key":"6665_CR33","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1093\/cid\/civ909","volume":"62","author":"DKM Ip","year":"2016","unstructured":"Ip DKM, Lau LLH, Chan K-H et al (2016) The dynamic relationship between clinical symptomatology and viral shedding in naturally acquired seasonal and pandemic influenza virus infections. Clin Infect Dis 62:431\u2013437. https:\/\/doi.org\/10.1093\/cid\/civ909","journal-title":"Clin Infect Dis"},{"key":"6665_CR34","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.antiviral.2009.01.006","volume":"82","author":"K Bauer","year":"2009","unstructured":"Bauer K, Richter M, Wutzler P, Schmidtke M (2009) Different neuraminidase inhibitor susceptibilities of human H1N1, H1N2, and H3N2 influenza A viruses isolated in Germany from 2001 to 2005\/2006. Antiviral Res 82:34\u201341. https:\/\/doi.org\/10.1016\/j.antiviral.2009.01.006","journal-title":"Antiviral Res"},{"key":"6665_CR35","doi-asserted-by":"publisher","first-page":"e0190877","DOI":"10.1371\/journal.pone.0190877","volume":"13","author":"N Tewawong","year":"2018","unstructured":"Tewawong N, Marathe BM, Poovorawan Y et al (2018) Neuraminidase inhibitor susceptibility and neuraminidase enzyme kinetics of human influenza A and B viruses circulating in Thailand in 2010\u20132015. PLoS One 13:e0190877. https:\/\/doi.org\/10.1371\/journal.pone.0190877","journal-title":"PLoS One"},{"key":"6665_CR36","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/irv.12044","volume":"7","author":"EA Govorkova","year":"2013","unstructured":"Govorkova EA (2013) Consequences of resistance: in vitro fitness, in vivo infectivity, and transmissibility of oseltamivir-resistant influenza A viruses. Influenza Other Respir Viruses 7:50\u201357. https:\/\/doi.org\/10.1111\/irv.12044","journal-title":"Influenza Other Respir Viruses"},{"key":"6665_CR37","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1089\/adt.2024.075","volume":"23","author":"G Atampugbire","year":"2025","unstructured":"Atampugbire G, Adomako EEA, Quaye O (2025) In vitro antiviral assays: a review of laboratory methods. Assay Drug Dev Technol 23:165\u2013179. https:\/\/doi.org\/10.1089\/adt.2024.075","journal-title":"Assay Drug Dev Technol"},{"key":"6665_CR38","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1080\/03007995.2019.1584505","volume":"35","author":"V Taieb","year":"2019","unstructured":"Taieb V, Ikeoka H, Ma F-F et al (2019) A network meta-analysis of the efficacy and safety of baloxavir marboxil versus neuraminidase inhibitors for the treatment of influenza in otherwise healthy patients. Curr Med Res Opin 35:1355\u20131364. https:\/\/doi.org\/10.1080\/03007995.2019.1584505","journal-title":"Curr Med Res Opin"},{"key":"6665_CR39","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1097\/INF.0000000000002747","volume":"39","author":"J Baker","year":"2020","unstructured":"Baker J, Block SL, Matharu B et al (2020) Baloxavir marboxil single-dose treatment in influenza-infected children. Pediatr Infect Dis J 39:700\u2013705. https:\/\/doi.org\/10.1097\/INF.0000000000002747","journal-title":"Pediatr Infect Dis J"},{"key":"6665_CR40","doi-asserted-by":"publisher","unstructured":"Chen S, Hua L (2025) Comparison of the efficacy and safety of baloxavir versus those of oseltamivir in pediatric patients with influenza: a meta-analysis. Front Microbiol 16. https:\/\/doi.org\/10.3389\/fmicb.2025.1672925","DOI":"10.3389\/fmicb.2025.1672925"},{"key":"6665_CR41","doi-asserted-by":"publisher","first-page":"10888","DOI":"10.1128\/JVI.00431-10","volume":"84","author":"KM Coombs","year":"2010","unstructured":"Coombs KM, Berard A, Xu W et al (2010) Quantitative proteomic analyses of influenza virus-infected cultured human lung cells. J Virol 84:10888\u201310906. https:\/\/doi.org\/10.1128\/JVI.00431-10","journal-title":"J Virol"},{"key":"6665_CR42","doi-asserted-by":"publisher","first-page":"20608","DOI":"10.1038\/s41598-022-24792-4","volume":"12","author":"W Bertrams","year":"2022","unstructured":"Bertrams W, H\u00f6nzke K, Obermayer B et al (2022) Transcriptomic comparison of primary human lung cells with lung tissue samples and the human A549 lung cell line highlights cell type specific responses during infections with influenza A virus. Sci Rep 12:20608. https:\/\/doi.org\/10.1038\/s41598-022-24792-4","journal-title":"Sci Rep"},{"key":"6665_CR43","doi-asserted-by":"publisher","first-page":"3848","DOI":"10.1016\/j.vaccine.2010.03.005","volume":"28","author":"AI Hussain","year":"2010","unstructured":"Hussain AI, Cordeiro M, Sevilla E, Liu J (2010) Comparison of egg and high yielding MDCK cell-derived live attenuated influenza virus for commercial production of trivalent influenza vaccine: in vitro cell susceptibility and influenza virus replication kinetics in permissive and semi-permissive cells. Vaccine 28:3848\u20133855. https:\/\/doi.org\/10.1016\/j.vaccine.2010.03.005","journal-title":"Vaccine"},{"key":"6665_CR44","doi-asserted-by":"publisher","first-page":"e0124651","DOI":"10.1371\/journal.pone.0124651","volume":"10","author":"X Liu","year":"2015","unstructured":"Liu X, Lai C, Wang K et al (2015) A functional role of fibroblast growth factor receptor 1 (FGFR1) in the suppression of influenza A virus replication. PLoS One 10:e0124651. https:\/\/doi.org\/10.1371\/journal.pone.0124651","journal-title":"PLoS One"},{"key":"6665_CR45","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1038\/s41564-025-01925-9","volume":"10","author":"EA Partlow","year":"2025","unstructured":"Partlow EA, Jaeggi-Wong A, Planitzer SD et al (2025) Influenza A virus rapidly adapts particle shape to environmental pressures. Nat Microbiol 10:784\u2013794. https:\/\/doi.org\/10.1038\/s41564-025-01925-9","journal-title":"Nat Microbiol"},{"key":"6665_CR46","doi-asserted-by":"publisher","first-page":"e112462","DOI":"10.1371\/journal.pone.0112462","volume":"9","author":"J Seladi-Schulman","year":"2014","unstructured":"Seladi-Schulman J, Campbell PJ, Suppiah S et al (2014) Filament-producing mutants of influenza A\/Puerto Rico\/8\/1934 (H1N1) virus have higher neuraminidase activities than the spherical wild-type. PLoS One 9:e112462. https:\/\/doi.org\/10.1371\/journal.pone.0112462","journal-title":"PLoS One"}],"container-title":["Archives of Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-026-06665-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00705-026-06665-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-026-06665-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T07:02:31Z","timestamp":1785135751000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00705-026-06665-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["6665"],"URL":"https:\/\/doi.org\/10.1007\/s00705-026-06665-7","relation":{},"ISSN":["0304-8608","1432-8798"],"issn-type":[{"value":"0304-8608","type":"print"},{"value":"1432-8798","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"assertion":[{"value":"10 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The present study was conducted with the approval and under the control of the Institutional Review Board of the Faculty of Medicine, Tottori University, Japan (no. 1981). All procedures involving human participants were in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Sample collection was conducted after obtaining informed consent from patients in collaborating medical facilities constituting of a hospital and three clinics. Samples were then shipped to the laboratory without patient identification.","order":2,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors report no conflict of interest.","order":3,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"200"}}